Candel Therapeutics

Candel Therapeutics an off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.

[Candel Therapeutics @CandelTx]

Our CEO @paulpetertak spoke with @endpts reporter @Nicole_DeFeudis about new long-term follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized #ProstateCancer.

https://t.co/QdbPZnk9uP

$CADL #Immunotherapy #CancerResearch

[Candel Therapeutics @CandelTx]

Our pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer is now published in @TheLancetOncol. 80.4% of treated patients achieved pathological complete response in 2-year biopsies vs. 63.6% on placebo.

https://t.co/BZygLAfJX0

$CADL

[Candel Therapeutics @CandelTx]

Kyle Donahue's 5-year journey with glioblastoma, featured in @ParadeMagazine, shows the potential of innovative treatments. After enrolling in our linoserpaturev (CAN-3110) trial, her tumors shrank and she’s regained much of her life.

https://t.co/CxVl1UpET6

#Glioblastoma $CADL

[Candel Therapeutics @CandelTx]

We are heading to the Jefferies Global Healthcare Conference in New York, sharing updates across our pipeline in prostate cancer, NSCLC, glioma, and our enLIGHTEN™ Discovery Platform.

https://t.co/NQu8hz499h

@paulpetertak #Biotech #Biopharma $CADL

[Candel Therapeutics @CandelTx]

We’ll be in Chicago for @ASCO!

Our team is available for meetings — reach out to connect and hear updates on our pipeline.

https://t.co/BFaFPDOCH7

#ASCO26 #Oncology #CancerResearch $CADL

[Candel Therapeutics @CandelTx]

Our CTDO Seshu Tyagarajan, Ph.D., discusses the analytical and validation work underpinning our BLA submission for aglatimagene besadenovec with @Lifesci_Connect, including our in-house QC capabilities and potency testing strategy.

https://t.co/qXhOpuvme8

#Biotech $CADL

[Candel Therapeutics @CandelTx]

On #ClinicalTrialsDay, we are grateful to the patients, investigators, and healthcare professionals driving progress in cancer care.

Learn more about our clinical programs: https://t.co/jn4xYQnmSy

#CancerResearch #Immunotherapy $CADL

[Candel Therapeutics @CandelTx]

Our CEO @paulpetertak is presenting at the Stifel 2026 Virtual Targeted Oncology Forum, sharing updates across our pipeline in prostate cancer, NSCLC, and recurrent glioma.

https://t.co/NQu8hz499h

#Oncology #Biotech $CADL

[Candel Therapeutics @CandelTx]

Announced Today - New extended follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer presented today at #AUA26.

Details here: https://t.co/RdMR2BsD34

#ProstateCancer #Immunotherapy $CADL

[Candel Therapeutics @CandelTx]

Today we announced our Q1 2026 financial results and provided corporate updates on our development programs.

Full details: https://t.co/U6jhHrN7Kx

$CADL

[Candel Therapeutics @CandelTx]

Proud to see our Chief Regulatory Officer Susan Stewart, J.D., spotlighted in @RAPSorg 50 for 50, honoring outstanding regulatory professionals for its 50th anniversary. Her expertise continues to be invaluable in guiding our regulatory strategy at Candel.
https://t.co/wicCc1Kcr3

[Candel Therapeutics @CandelTx]

This #NationalCancerResearchMonth, we are proud to be advancing multimodal viral immunotherapies across prostate cancer, NSCLC, and recurrent glioblastoma, with key milestones ahead in 2026.

https://t.co/liFL6tjiA0

#CancerResearch #Immunotherapy $CADL

[Candel Therapeutics @CandelTx]

We are heading to #AUA26!

Join us for new extended follow-up data from our phase 3 trial of aglatimagene in localized #prostatecancer, presented by Dr. Mark Garzotto in a plenary session.

Visit our booth to connect with our team.

https://t.co/E8KjXJHmrz

@AmerUrological

[Candel Therapeutics @CandelTx]

We will host a conference call on May 15 to discuss extended phase 3 data for aglatimagene besadenovec in localized #ProstateCancer, with thought leaders Dr. Daniel George, Dr. Neal Shore, and Dr. Jonathan Tward.

Registration details: https://t.co/MGG9pj7lkF

#AUA2026 $CADL

[Candel Therapeutics @CandelTx]

At #BioEquityEurope, our CEO @paulpetertak presented phase 2 data for aglatimagene in advanced NSCLC.
50% of patients survived beyond 24 months despite prior immune checkpoint inhibitor failure, with a long-term survival tail supporting phase 3 initiation.

@BioCentury #CADL

[Candel Therapeutics @CandelTx]

At #BioEquityEurope, our CEO @paulpetertak joined a panel on Patient Engagement Strategies, discussing how the patient perspective should shape innovation in drug discovery and development.

https://t.co/DOhtQtSfUQ

@BioCentury #PatientEngagement #PatientFirst #Biotech $CADL

[Candel Therapeutics @CandelTx]

We are presenting at BioEquity Europe 2026 in Prague!

Connect with our team to learn more about our viral immunotherapy pipeline across prostate cancer, NSCLC, and glioma.

https://t.co/DAhqieJDGT

@paulpetertak @BioCentury

#ProstateCancer #Immunotherapy $CADL

[Candel Therapeutics @CandelTx]

Our CEO @paulpetertak, M.D., Ph.D., and CTDO Seshu Tyagarajan, Ph.D., discuss our sprint to BLA submission for aglatimagene besadenovec (CAN-2409) with @Lifesci_connect, covering our partner-led manufacturing strategy and commercial readiness.

https://t.co/SxtMFIWgkS

$CADL

[Candel Therapeutics @CandelTx]

Today we announced a commercialization agreement with @EVERSANA to support potential U.S. launch of aglatimagene besadenovec (CAN-2409) for localized #ProstateCancer, ahead of our planned BLA submission in Q4 2026.

https://t.co/roqHSI0g4X

$CADL

[Candel Therapeutics @CandelTx]

We’re attending @USAIC's 20th Annual BioPharma & Healthcare Summit in Boston this Thursday, joining global leaders in biopharma and healthcare innovation.

@paulpetertak #USAIC26 #Biopharma $CADL